Author:
Hoskin Peter,Sartor Oliver,O'Sullivan Joe M,Johannessen Dag Clement,Helle Svein I,Logue John,Bottomley David,Nilsson Sten,Vogelzang Nicholas J,Fang Fang,Wahba Mona,Aksnes Anne-Kirsti,Parker Christopher
Reference23 articles.
1. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004
2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004
3. Clinical practice guidelines in oncology—prostate cancer (version 2.2014),2014
4. Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity;Schutz;Crit Rev Oncol Hematol,2014
5. Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population;Engel-Nitz;Cancer Manag Res,2011
Cited by
341 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献